AstraZeneca PLC closed 16.13% short of its 52-week high of £133.88, which the company reached on September 3rd.

Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

The FTSE 100 is packed with top-notch companies that can form the building blocks of a quality Stocks and Shares ISA ...

Multinational pharmaceutical company AstraZeneca is bullish about China's role as a global innovation powerhouse, underpinned ...

Spain ranks first in Europe for clinical trials and is attracting investment in life sciences, but faces intense competition ...

AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes for a potential blockbuster that could be part of a powerful combination ...

AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer ...

Learn more about whether AstraZeneca PLC or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether AstraZeneca PLC or Corcept Therapeutics Incorporated is a better investment based on AAII's A+ ...

AstraZeneca has vowed to spend over $10 billion on R&D deals in Asia, focusing on China, amid ongoing fraud scandal ...

J.P. Morgan analyst James Gordon maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £140.00. The ...